IpiNovyx Bio is a biopharmaceutical company dedicated to the development of next-generation proteasome inhibitors that will revolutionize the treatment of disease. At the heart of IpiNovyx’s mission is the development of a platform capable of delivering best-in-class proteasome modulating therapeutics designed to target cells responsible in individual diseases. These innovative small molecule inhibitors are being developed with precision to selectively target the immunoproteasome — a key component of the immune system responsible for degrading intracellular proteins, as well as the constitutive proteasome which plays key roles in maintaining malignant cell viability. IpiNovyx’s approach focuses on developing bespoke proteasome inhibitors with superior efficacy and safety profiles compared to current agents, offering patients a safer and more effective alternative to conventional therapies. The foundational science behind IpiNovyx’s technology stems from leading research conducted at Weill Cornell Medicine and the Hospital for Special Surgery (HSS) Research Institute. To date, discovery efforts have led to the identification of highly selective and reversible proteasome inhibitors which are being developed for bespoke applications in various disease settings. IpiNovyx Bio has to-date closed a $10 million seed financing round; alongside Orange Grove Bio, prominent investors include Eli Lilly and Company, Viva BioInnovator, Opaleye Management, and Alexandria Venture Investments. With this backing, IpiNovyx Bio is poised to advance its lead drug candidates through preclinical studies and towards clinical trials, with the ultimate goal of delivering innovative treatments for oncology, autoimmune and inflammatory diseases. The company’s lead program is progressing toward the clinic to realize the full potential of proteasome targeting in Oncology, with a mid-2026 target timeline for entry into the clinic.